An Israeli algorithm may predict if cancer patients will respond to treatment. Oncohost combines life-science research and advanced machine-learning technology to develop personalized strategies to maximize the success of cancer therapy. By analyzing the patient’s proteins, the company aims to understand patients’ unique response to therapy and overcome resistance to therapy, one of the major obstacles in clinical oncology.
“Today, when a physician treats a patient, he has no idea if the patient is going to respond or not,” states Oncohost CEO Ofer Sharon. “Our platform will assess in a more educated way whether the patient is likely to ever respond..and provide the doctor with clinical insights as to what needs to be done to improve the patient’s chances of response.”
Oncohost founder and chief scientific adviser, Professor Yuval Shaked, serves as the head of the Technion Integrated Cancer Center.